LONDON – The commercial prospects of Vernalis plc are about to be transformed following FDA approval of its lead prescription cough-cold product, Tuzistra. Read More
The Medicines Co. may have prospectively eased the pain of generic competition that looms for flagship product Angiomax (bivalirudin) – and may have helped stanch the money hemorrhage that would result – by winning FDA approval of two drug-device combo therapies: one for patients who need opioid analgesia in the hospital and another to control bleeding. Read More
HONG KONG – In the same week that it started construction of the largest biological manufacturing facility in China, Wuxi Pharmatech Inc. also received a privatization proposal from its founder and chairman. Read More
Much of the excitement in immuno-oncology has been focused on killer T cells and dendritic cells. But, Edgar Engleman told BioWorld Today, "the immune system is designed to work as a team. . . . There is cooperation among the different branches of the armed services, as it were." Read More
A recent bidding war on a government tender in Norway for an infliximab biosimilar resulted in a 69 percent discount from the innovator and a rapid market uptake of the follow-on, proving that physicians and patients will flock to a biosimilar – if the price is right. Read More
a href="https://cortellis.thomsonreuterslifesciences.com/ngg/qsearch/Exelixis%0D" target="_blank">Exelixis Inc. shares (NASDAQ:EXEL) climbed as much as 14 percent Friday on better-than-expected first quarter earnings, halved R&D costs and the hope that cabozantinib, which fizzled in a pivotal study for prostate cancer, would blaze brighter in METEOR, a phase III study in metastatic renal cell carcinoma (mRCC) reporting top-line data by the end of the second quarter or early in the third quarter. Read More
Northwest Biotherapeutics Inc., of Bethesda, Md., closed on the $28.5 million second tranche of a $40 million investment from Woodford investment funds in the UK. Woodford first invested $25 million in November 2014. Read More
Celgene Corp., of Summit, N.J., reported results from a pre-specified secondary endpoint analysis of MDS-005, a randomized, placebo-controlled phase III study of Revlimid (lenalidomide) compared with placebo in patients with non-del-5q myelodysplastic syndromes. Read More
Eisai Inc., of Woodcliff Lake, N.J., said it entered a settlement with Glenmark Pharmaceutials Ltd., of Mumbai, India, to resolve the patent litigation relating to Eisai's Banzel (rufinamide) in the U.S. Read More
Researchers from Duke University have identified a method to potentially separate motor symptoms of the Parkinson's disease (PD) drug L-dopa from its side effects. Read More
